Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

LongeVC, an international investor based in Latvia, has injected an unspecified sum into Cambridge company Constructive Bio ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Opens in a new tab or window Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose.

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...